Literature DB >> 30805885

Quantitative Imaging of Morphometric and Metabolic Signatures Reveals Heterogeneity in Drug Response of Three-Dimensional Mammary Tumor Spheroids.

V Krishnan Ramanujan1,2,3,4.   

Abstract

PURPOSE: In order to monitor the drug responses of three-dimensional mammary tumor spheroids and to elucidate the role of inter- and intra-spheroid heterogeneity in determining drug sensitivity in the spheroids, an integrated image analysis framework was developed for morphometric and metabolic characterization of the three-dimensional tumor spheroids. PROCEDURE: Three-dimensional spheroid cultures of primary mammary tumor epithelial cells isolated from freshly excised tumors from a transgenic mouse model of adenocarcinoma (MMTV-PyMT) were imaged by using vital dyes and mitochondrial membrane potential markers. Custom-developed java and python program codes facilitated image processing, numerical computation, and graphical analysis of large datasets generated from the experiments. A panel of cancer drugs (rapamycin, BEZ235, MK2206, and flavopiridol) was tested to determine the degree of drug sensitivity as well as heterogeneity in drug response.
RESULTS: A new quantitative metric (growth/toxicity) was developed based on morphometric parameters that were found to track the growth and apoptotic cell populations. Further, this study identified two parameters, namely, skew and kurtosis-which report the spatial heterogeneity in mitochondrial metabolism within the spheroids. The results of this study show that three-dimensional tumor spheroids selectively respond to cancer drugs depending on the specific metabolic pathways (AKT inhibition pathway in the present study), and there exists significant heterogeneity in the untreated tumor spheroids. Drug sensitivity of the spheroids was found to be associated with significant alterations in mitochondrial heterogeneity within the spheroids.
CONCLUSIONS: In conclusion, the quantitative imaging of morphometric and metabolic analysis in large image datasets can serve as an excellent tool box for characterizing tumor heterogeneity in three-dimensional tumor spheroids and potentially, in intact tumors as well.

Entities:  

Keywords:  Breast cancer; Drug response; Image analysis; Mammary tumor organoids; Mitochondria; Three-dimensional spheroids; Tumor heterogeneity

Mesh:

Substances:

Year:  2019        PMID: 30805885     DOI: 10.1007/s11307-019-01324-7

Source DB:  PubMed          Journal:  Mol Imaging Biol        ISSN: 1536-1632            Impact factor:   3.488


  33 in total

1.  Metabolic imaging in multiple time scales.

Authors:  V Krishnan Ramanujan
Journal:  Methods       Date:  2013-09-04       Impact factor: 3.608

Review 2.  Flavopiridol, an inhibitor of transcription: implications, problems and solutions.

Authors:  Mikhail V Blagosklonny
Journal:  Cell Cycle       Date:  2004-12-01       Impact factor: 4.534

3.  The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.

Authors:  Hongtao Wang; Fang Huang; Jian Wang; Peng Wang; Wenjie Lv; Liu Hong; Shanhu Li; Jianguang Zhou
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 4.  Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.

Authors:  Antoinette R Tan; Sandra M Swain
Journal:  Semin Oncol       Date:  2002-06       Impact factor: 4.929

5.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

6.  Characterizing the metabolic heterogeneity in human breast cancer xenografts by 3D high resolution fluorescence imaging.

Authors:  He N Xu; Gang Zheng; Julia Tchou; Shoko Nioka; Lin Z Li
Journal:  Springerplus       Date:  2013-02-28

7.  The molecular portraits of breast tumors are conserved across microarray platforms.

Authors:  Zhiyuan Hu; Cheng Fan; Daniel S Oh; J S Marron; Xiaping He; Bahjat F Qaqish; Chad Livasy; Lisa A Carey; Evangeline Reynolds; Lynn Dressler; Andrew Nobel; Joel Parker; Matthew G Ewend; Lynda R Sawyer; Junyuan Wu; Yudong Liu; Rita Nanda; Maria Tretiakova; Alejandra Ruiz Orrico; Donna Dreher; Juan P Palazzo; Laurent Perreard; Edward Nelson; Mary Mone; Heidi Hansen; Michael Mullins; John F Quackenbush; Matthew J Ellis; Olufunmilayo I Olopade; Philip S Bernard; Charles M Perou
Journal:  BMC Genomics       Date:  2006-04-27       Impact factor: 3.969

8.  Molecular characterization of breast cancer cell response to metabolic drugs.

Authors:  Lucía Trilla-Fuertes; Angelo Gámez-Pozo; Jorge M Arevalillo; Mariana Díaz-Almirón; Guillermo Prado-Vázquez; Andrea Zapater-Moros; Hilario Navarro; Rosa Aras-López; Irene Dapía; Rocío López-Vacas; Paolo Nanni; Sara Llorente-Armijo; Pedro Arias; Alberto M Borobia; Paloma Maín; Jaime Feliú; Enrique Espinosa; Juan Ángel Fresno Vara
Journal:  Oncotarget       Date:  2018-01-08

9.  Data integration from pathology slides for quantitative imaging of multiple cell types within the tumor immune cell infiltrate.

Authors:  Zhaoxuan Ma; Stephen L Shiao; Emi J Yoshida; Steven Swartwood; Fangjin Huang; Michael E Doche; Alice P Chung; Beatrice S Knudsen; Arkadiusz Gertych
Journal:  Diagn Pathol       Date:  2017-09-18       Impact factor: 2.644

Review 10.  Recent Advances in the Treatment of Breast Cancer.

Authors:  Christy W S Tong; Mingxia Wu; William C S Cho; Kenneth K W To
Journal:  Front Oncol       Date:  2018-06-14       Impact factor: 6.244

View more
  2 in total

1.  Phasor S-FLIM: a new paradigm for fast and robust spectral fluorescence lifetime imaging.

Authors:  Lorenzo Scipioni; Alessandro Rossetta; Giulia Tedeschi; Enrico Gratton
Journal:  Nat Methods       Date:  2021-04-15       Impact factor: 28.547

2.  Commemorating Britton Chance.

Authors:  Lin Z Li; He N Xu; Arjun G Yodh
Journal:  Mol Imaging Biol       Date:  2019-06       Impact factor: 3.488

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.